Why is ICH E9 Important in Cancer Clinical Trials?
Cancer clinical trials are inherently complex due to the heterogeneity of the disease, varying treatment responses, and diverse patient populations. Adhering to ICH E9 ensures that the statistical methodologies employed are appropriate for addressing these complexities, thus providing reliable and valid results that can inform clinical practice and regulatory decisions.
